Search

Coloplast A-S (Class B)

Închisă

535.6 -0.56

Rezumat

Modificarea prețului

24h

Curent

Minim

531.6

Maxim

539.6

Indicatori cheie

By Trading Economics

Venit

70M

875M

Vânzări

2M

7B

P/E

Medie Sector

33.065

90.422

EPS

3.88

Randament dividend

4.26

Marjă de profit

12.572

Angajați

16,744

EBITDA

2B

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

+11.86% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

4.26%

2.13%

Următoarele câștiguri

6 feb. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

-2.3B

120B

Deschiderea anterioară

536.16

Închiderea anterioară

535.6

Coloplast A-S (Class B) Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

2 feb. 2026, 23:52 UTC

Achiziții, Fuziuni, Preluări

Elliott Management Doesn't Plan to Tender Its Shares at the Current Terms

2 feb. 2026, 23:52 UTC

Achiziții, Fuziuni, Preluări

Elliott Management: Toyota Fudosan Revised Tender Offer for Toyota Industries 'Very Significantly Undervalues' Company

2 feb. 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

2 feb. 2026, 23:38 UTC

Market Talk

Gold Rises on Likely Technical Recovery, Dip-Buying Interest -- Market Talk

2 feb. 2026, 23:28 UTC

Market Talk

SpaceX, xAI Deal Further Consolidates Musk's Businesses -- Market Talk

2 feb. 2026, 23:23 UTC

Câștiguri

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- 2nd Update

2 feb. 2026, 22:57 UTC

Câștiguri

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 feb. 2026, 22:22 UTC

Achiziții, Fuziuni, Preluări

What the Blockbuster SpaceX--xAI Merger Can Mean for Tesla Stock -- Barrons.com

2 feb. 2026, 22:08 UTC

Market Talk

Australian Inflation Woes Rooted In Excess Govt Spending -- Market Talk

2 feb. 2026, 21:51 UTC

Câștiguri

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 feb. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

2 feb. 2026, 21:49 UTC

Câștiguri

Disney's Streaming Profit Surges as CEO Decision Approaches -- 5th Update

2 feb. 2026, 21:39 UTC

Câștiguri

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 feb. 2026, 21:36 UTC

Câștiguri

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- Update

2 feb. 2026, 21:34 UTC

Câștiguri

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 feb. 2026, 21:28 UTC

Achiziții, Fuziuni, Preluări

What a SpaceX--xAI Merger Could Mean for Tesla Stock -- Barrons.com

2 feb. 2026, 21:23 UTC

Câștiguri

BYD, Chinese EV Stock Plunge On Weak Data. What That Means for Tesla Stock. -- Barrons.com

2 feb. 2026, 21:19 UTC

Câștiguri

Palantir Technologies: U.S. Commercial Business Growing at 'Astonishing' Rate, Generating $507 Million Last Quarter, 137% Increase Over the Same Period the Year Before >PLTR

2 feb. 2026, 21:17 UTC

Câștiguri

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- WSJ

2 feb. 2026, 21:17 UTC

Câștiguri

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 feb. 2026, 21:10 UTC

Câștiguri

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 feb. 2026, 21:08 UTC

Câștiguri

Palantir Technologies: Rule of 40 Score Is Now 127% >PLTR

2 feb. 2026, 21:07 UTC

Câștiguri

Palantir Technologies: Sees 2026 U.S. Comml Rev in Excess of $3.144B, Representing Growth Rate of at Least 115% >PLTR

2 feb. 2026, 21:05 UTC

Câștiguri

Palantir Technologies 4Q Net $608.7M >PLTR

2 feb. 2026, 21:05 UTC

Câștiguri

Palantir Technologies 4Q Rev $1.41B >PLTR

2 feb. 2026, 21:05 UTC

Câștiguri

Palantir Technologies Sees 1Q Rev $1.53B-$1.54B >PLTR

2 feb. 2026, 21:05 UTC

Câștiguri

Palantir Technologies Sees FY Rev $7.18B-$7.2B >PLTR

2 feb. 2026, 21:05 UTC

Câștiguri

Palantir Technologies 4Q Adj EPS 25c >PLTR

2 feb. 2026, 21:05 UTC

Câștiguri

Palantir Technologies 4Q EPS 24c >PLTR

2 feb. 2026, 20:40 UTC

Market Talk

Treasury Yields, Dollar Rise Amid Signs of Resilient U.S. Economy -- Market Talk

Coloplast A-S (Class B) Așteptări

Obiectiv de preț

By TipRanks

11.86% sus

Prognoză pe 12 luni

Medie 901.38 DKK  11.86%

Maxim 1,056 DKK

Minim 720 DKK

În baza a 8 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruColoplast A-S (Class B) - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

8 ratings

2

Cumpărare

4

Păstrare

2

Vânzare

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Coloplast A-S (Class B)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
help-icon Live chat